TY - JOUR
T1 - The 5-HT 2A receptor and serotonin transporter in Asperger's Disorder
T2 - A PET study with [ 11C]MDL 100907 and [ 11C]DASB
AU - Girgis, Ragy R.
AU - Slifstein, Mark
AU - Xu, Xiaoyan
AU - Frankle, W. Gordon
AU - Anagnostou, Evdokia
AU - Wasserman, Stacey
AU - Pepa, Lauren
AU - Kolevzon, Alexander
AU - Abi-Dargham, Anissa
AU - Laruelle, Marc
AU - Hollander, Eric
N1 - Funding Information:
Dr. Girgis has received research support from Janssen and Lilly through APIRE and a travel stipend from Lilly, Forest, and Elsevier Science through the Society of Biological Psychiatry. In the last 3 years, Dr. Slifstein has served as a consultant for Amgen, Inc. and GlaxoSmithKline, and has received research support from Intracellular Therapies, Inc. Dr. Wasserman, Ms. Pepa, Dr. Xu, and Dr. Laruelle have nothing to disclose. Over the last 3 years, Dr. Kolevzon has received research support from Neuropharm, Bristol-Myers Squibb, Johnson & Johnson, and Curemark, LLC. Dr. Frankle is a consultant for Sepracor, Inc. Dr. Anagnostou has non-paid consultations to Neuropharm and Proximagen. In the last 2 years, Dr. Abi-Dargham has been a speaker for BMS-Otsuka and Sunovion, received research support from Forest and GSK, and served as a consultant for Lundbeck and Boehringer Ingelhein. Dr. Hollander has applied for patents for the use of oxytocin and memantine in autism.
PY - 2011/12/30
Y1 - 2011/12/30
N2 - Evidence from biochemical, imaging, and treatment studies suggest abnormalities of the serotonin system in autism spectrum disorders, in particular in frontolimbic areas of the brain. We used the radiotracers [ 11C]MDL 100907 and [ 11C]DASB to characterize the 5-HT 2A receptor and serotonin transporter in Asperger's Disorder. Seventeen individuals with Asperger's Disorder (age=34.3±11.1years) and 17 healthy controls (age=33.0±9.6years) were scanned with [ 11C]MDL 100907. Of the 17 patients, eight (age=29.7±7.0years) were also scanned with [ 11C]DASB, as were eight healthy controls (age=28.7±7.0years). Patients with Asperger's Disorder and healthy control subjects were matched for age, gender, and ethnicity, and all had normal intelligence. Metabolite-corrected arterial plasma inputs were collected and data analyzed by two-tissue compartment modeling. The primary outcome measure was regional binding potential BP ND. Neither regional [ 11C]MDL 100907 BP ND nor [ 11C]DASB BP ND was statistically different between the Asperger's and healthy subjects. This study failed to find significant alterations in binding parameters of 5-HT 2A receptors and serotonin transporters in adult subjects with Asperger's Disorder.
AB - Evidence from biochemical, imaging, and treatment studies suggest abnormalities of the serotonin system in autism spectrum disorders, in particular in frontolimbic areas of the brain. We used the radiotracers [ 11C]MDL 100907 and [ 11C]DASB to characterize the 5-HT 2A receptor and serotonin transporter in Asperger's Disorder. Seventeen individuals with Asperger's Disorder (age=34.3±11.1years) and 17 healthy controls (age=33.0±9.6years) were scanned with [ 11C]MDL 100907. Of the 17 patients, eight (age=29.7±7.0years) were also scanned with [ 11C]DASB, as were eight healthy controls (age=28.7±7.0years). Patients with Asperger's Disorder and healthy control subjects were matched for age, gender, and ethnicity, and all had normal intelligence. Metabolite-corrected arterial plasma inputs were collected and data analyzed by two-tissue compartment modeling. The primary outcome measure was regional binding potential BP ND. Neither regional [ 11C]MDL 100907 BP ND nor [ 11C]DASB BP ND was statistically different between the Asperger's and healthy subjects. This study failed to find significant alterations in binding parameters of 5-HT 2A receptors and serotonin transporters in adult subjects with Asperger's Disorder.
KW - 5-HT receptor
KW - Asperger's Disorder
KW - Autism spectrum disorders
KW - Positron emission tomography
KW - Serotonin
KW - Serotonin transporter
UR - http://www.scopus.com/inward/record.url?scp=82455164162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82455164162&partnerID=8YFLogxK
U2 - 10.1016/j.pscychresns.2011.04.007
DO - 10.1016/j.pscychresns.2011.04.007
M3 - Article
C2 - 22079057
AN - SCOPUS:82455164162
SN - 0925-4927
VL - 194
SP - 230
EP - 234
JO - Psychiatry Research - Neuroimaging
JF - Psychiatry Research - Neuroimaging
IS - 3
ER -
